1. Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression. Issue 2 (13th October 2020) Authors: Katz, Eva G.; Hough, David; Doherty, Teodora; Lane, Rosanne; Singh, Jaskaran; Levitan, Bennett Journal: Clinical pharmacology & therapeutics Issue: Volume 109:Issue 2(2021) Page Start: 536 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression. Issue 2 (13th October 2020) Authors: Katz, Eva G.; Hough, David; Doherty, Teodora; Lane, Rosanne; Singh, Jaskaran; Levitan, Bennett Journal: Clinical pharmacology & therapeutics Issue: Volume 109:Issue 2(2021) Page Start: 536 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗